Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$14.35 +1.5%	$12.28	$5.31 ▼ $17.43	$1.07B	1.71	1.97 million shs	4.16 million shs
CRON Cronos Group	$2.60 +1.6%	$2.16	$1.60 ▼ $2.77	$995.90M	1.01	1.89 million shs	6.25 million shs
NMRA Neumora Therapeutics	$1.76	$1.43	$0.61 ▼ $17.19	$285.03M	2.91	1.99 million shs	303,722 shs
PRAX Praxis Precision Medicines	$45.99 -2.0%	$49.05	$26.70 ▼ $91.83	$968.09M	2.62	447,647 shs	186,945 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	+1.07%	+4.59%	+18.03%	+15.71%	+129.17%
CRON Cronos Group	+0.39%	+5.79%	+24.27%	+24.88%	+16.36%
NMRA Neumora Therapeutics	+1.15%	+9.32%	-22.81%	+144.89%	-84.78%
PRAX Praxis Precision Medicines	-2.05%	+3.69%	-15.69%	+22.03%	-12.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	2.7079 of 5 stars	3.4	1.0	3.8	0.0	1.9
CRON Cronos Group	0.7843 of 5 stars	0.0	3.0	2.5	0.0	1.3
NMRA Neumora Therapeutics	2.5765 of 5 stars	3.1	3.0	2.3	2.5	0.6
PRAX Praxis Precision Medicines	1.6927 of 5 stars	3.4	1.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.86	Moderate Buy	$17.33	20.87% Upside
CRON Cronos Group	0.00	N/A	N/A	N/A
NMRA Neumora Therapeutics	2.22	Hold	$7.14	308.40% Upside
PRAX Praxis Precision Medicines	2.75	Moderate Buy	$85.88	86.78% Upside

Current Analyst Ratings Breakdown

Latest NMRA, PRAX, CRMD, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/30/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	24.63	N/A	N/A	$2.96 per share	4.84
CRON Cronos Group	$117.61M	8.44	$0.00 per share	5,480.10	$2.95 per share	0.88
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.13 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	113.19	N/A	N/A	$19.21 per share	2.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.75	19.12	15.26	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
CRON Cronos Group	$41.08M	$0.05	51.82	86.37	N/A	14.19%	-3.78%	-3.62%	11/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.57	N/A	N/A	N/A	N/A	-98.95%	-87.68%	11/11/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	11/5/2025 (Estimated)

Latest NMRA, PRAX, CRMD, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
8/6/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	-$0.33	+$0.05	-$0.33	N/A	N/A
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	7.82	7.52
CRON Cronos Group	N/A	24.65	23.53
NMRA Neumora Therapeutics	0.11	10.54	10.54
PRAX Praxis Precision Medicines	N/A	6.31	6.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
CRON Cronos Group	8.71%
NMRA Neumora Therapeutics	47.65%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
CRON Cronos Group	7.30%
NMRA Neumora Therapeutics	26.80%
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
CRON Cronos Group	450	383.04 million	355.08 million	Optionable
NMRA Neumora Therapeutics	108	161.95 million	118.54 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable

NMRA, PRAX, CRMD, and CRON Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 27 at 10:00 AM | prnewswire.com

Candriam S.C.A. Lowers Holdings in Praxis Precision Medicines, Inc. $PRAX

August 26 at 4:49 AM | marketbeat.com

Algert Global LLC Invests $814,000 in Praxis Precision Medicines, Inc. $PRAX

August 26 at 4:05 AM | marketbeat.com

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

August 25 at 4:01 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 25 at 12:13 PM | globenewswire.com

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

August 23, 2025 | globenewswire.com

Aberdeen Group plc Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX

August 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 22, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 21, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $85.88 Consensus PT from Analysts

August 20, 2025 | americanbankingnews.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of "Moderate Buy" by Brokerages

August 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 17, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 16, 2025 | prnewswire.com

Protect Your Investment: Contact Levi & Korsinsky About the Praxis Precision Medicines, Inc. (PRAX) Investigation

August 14, 2025 | theglobeandmail.com

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. ...

August 14, 2025 | gurufocus.com

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

August 14, 2025 | prnewswire.com

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

August 13, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 13, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 11, 2025 | prnewswire.com

Chardan Capital Brokers Lower Earnings Estimates for PRAX

August 11, 2025 | marketbeat.com

XTX Topco Ltd Purchases Shares of 10,043 Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA, PRAX, CRMD, and CRON Company Descriptions

CorMedix NASDAQ:CRMD

$14.35 +0.21 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$14.32 -0.03 (-0.21%)

As of 05:26 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Cronos Group NASDAQ:CRON

$2.60 +0.04 (+1.56%)

Closing price 04:00 PM Eastern

Extended Trading

$2.59 -0.01 (-0.35%)

As of 05:34 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Neumora Therapeutics NASDAQ:NMRA

$1.76 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 -0.02 (-1.08%)

As of 05:37 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$45.99 -0.93 (-1.98%)

Closing price 04:00 PM Eastern

Extended Trading

$46.02 +0.02 (+0.05%)

As of 05:36 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time